Ipamorelin works by binding to the ghrelin receptor in the pituitary gland, prompting the release of growth hormone
Legislative authorization for the wildly popular program lapsed in late 2024, and although its direct impact had been blunted due to language permitting FDA to award PRVs until September 30, 2026 so long as the underlying products had received RPD designations before December 20, 2024, uncertainty over the programs fate was beginning to weigh on product developers and investors alike
Gut microbiota: the conductor in the orchestra of immuneneuroendocrine communication
Tolerance Some patients do better on one medication than the other
Prioritise protein to protect muscle Research suggests that people losing weight on GLP-1 receptor agonists often fall well short of recommended protein targets, which can accelerate muscle loss
An important note for GLP1 GI AEs is that standard approaches may not correctly characterise the incidence of GI AEs given the mechanism of action of GLP1 RAs, which decrease gastric emptying and suppress appetite to reduce overall food intake
